Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Fosphenytoin→

Fosphenytoin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
93390-81-9
Molecular formula
C16H15N2O6P
Molecular weight
362.27 g/mol
Drug class
Phenytoin prodrughydantoin antiseizure medicine
Mechanism of action
Fosphenytoin is rapidly converted to phenytoin. Phenytoin stabilises neuronal membranes by prolonging the inactivated state of voltage-gated sodium channels, limiting sustained high-frequency neuronal firing.
Indications / reported uses
  • Control of generalised tonic-clonic status epilepticus
  • Prevention and treatment of seizures occurring during neurosurgery
  • Short-term substitution for oral phenytoin when oral administration is not possible; route and loading dose are product-specific

Sources: US DailyMed — CEREBYX (fosphenytoin) · NLM MeSH — Fosphenytoin · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Fosphenytoin Environmental Risk Assessment (ERA) (the Fosphenytoin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.